nVerses Capital’s Amgen AMGN Stock Holding History

nVerses Capital’s Portfolio AMGN Stock Details AMGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-900	Closed	-$290K	–	42
2024 Q3	$290K	Buy	900 +800	+800%	+$262K	0.13%	247
2024 Q2	$31.2K	Buy	+100	New	+$29.4K	0.02%	688

Other funds holding AMGN

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Koshinski Asset Management Decatur, Illinois $1.88B AUM 29.07% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

nVerses Capital's AMGN Position: Q4 2024 in Review

nVerses Capital sold out of Amgen (AMGN) in Q4 2024, closing a stake of 900 shares — an estimated $290K sold.

nVerses Capital first reported a position in AMGN in Q2 2024 and held it in 2 quarters. The position peaked at $290K in Q3 2024. 2,856 funds tracked by Wall St. Rank hold AMGN as of Q4 2024.

nVerses Capital reported no remaining Amgen position as of Q4 2024 after selling out during the quarter.
nVerses Capital sold 900 Amgen shares in Q4 2024, an estimated $290K.
nVerses Capital first reported a position in Amgen in Q2 2024 and held it in 2 quarters.
nVerses Capital's Amgen position peaked at $290K in Q3 2024.
2,856 funds tracked by Wall St. Rank held Amgen as of Q4 2024.

Based on nVerses Capital's 13F filing for Q4 2024.